Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)

Exclusion Criteria

• •History of or any current (treated) endocrine abnormality;
• •History of ovarian hyper-response or history of ovarian hyperstimulation syndrome (OHSS);
• •History of or current polycystic ovary syndrome (PCOS);
• •More than 20 basal antral follicles (size: \<11 mm, both ovaries combined) as measured on USS in the early follicular phase (menstrual cycle day 2-5);
• •Less than 2 ovaries or any other ovarian abnormality, including endometrioma \>10 mm (visible on USS);
• •Presence of unilateral or bilateral hydrosalpinx (visible on USS);
• •More than three unsuccessful COS cycles since the last established ongoing pregnancy (if applicable);
• •History of non- or low ovarian response to FSH/human menopausal gonadotrophin (hMG) treatment;
• •FSH \> 12 IU/L or luteinizing hormone (LH) \> 12 IU/L as measured by the local laboratory (sample taken during the early follicular phase: menstrual cycle day 2-5);
• •Any clinically relevant abnormal laboratory value based on a sample taken during the screening phase, including abnormal cervical smear (Papanicolaou \[PAP\]\>=III, cervical intraepithelial neoplasia \[CIN\]\>=1);
• •Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts) or GnRH antagonists (e.g. hypersensitivity, pregnancy/lactation);
• •Recent history of or current epilepsy, human immunodeficiency virus (HIV) infection, thrombophilia, diabetes or cardiovascular, gastro-intestinal, hepatic, renal, or pulmonary disease;
• •Abnormal karyotyping of the participant or her partner (if karyotyping is performed);
• •History or presence of alcohol or drug abuse within 12 months prior to signing informed consent;
• •Previous use of corifollitropin alfa;
• •Use of hormonal preparations within 1 month prior to screening;
• •Administration of investigational drugs within three months prior to signing informed consent.